On September 10,2025, the BIOHK2025 Hong Kong International Biotechnology Forum and Exhibition grandly commenced at the Hong Kong Convention and Exhibition Centre. As one of the largest and most influential international biotechnology events in Asia, BIOHK2025, themed 'Igniting the Light of Biotechnology,' focused on cutting-edge fields such as innovative drugs, artificial intelligence, stem cells, and gene therapy, attracting top scientists, industry leaders, and representatives from investment institutions from over 20 countries and regions worldwide.

Hosted by the Hong Kong Biotechnology Association, this forum featured 13 keynote presentations, over 40 parallel sessions, and more than 100 exhibition booths, attracting a cumulative audience of over 5,000 professionals. At the opening ceremony, distinguished guests including Professor Yu Changhai, Chairman of the Hong Kong Society for Biotechnology; Mr. Leung Chun-ying, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC); Professor Sun Dong, Secretary for Innovation, Technology and Industry of the HKSAR Government; Professor Lo Chung-mau, Secretary for Health of the HKSAR Government; and Ambassador Johta Gen, Chairman and CEO of DEFTA Partners Group, were in attendance and delivered speeches.

Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley, was invited to attend the opening ceremony and jointly served as co-chair of the forum 'A New Era in Stem Cells & Cell Therapy' with Dr. Gina Jiang, Director of the Hong Kong Biotechnology Research Institute. The Forum centered on high-level discussions regarding frontier breakthroughs in Cell and Gene Therapy (CGT) and their industrial application, garnering widespread attention.

On the same afternoon, Professor Shi Yuanyuan presided over the "Hong Kong Closed-door Meeting on Cell Therapy Regulation and Development". Professor Wang Jianxun, Chief Scientist of Shenzhen Cell Valley, and Dr. Fu Yuchen, Assistant to the Chairman, attended the meeting. The closed-door meeting gathered over 20 heavyweight guests, including representatives from the Hong Kong Department of Health, the National Health Commission Clinical Research Center, former FDA cell drug approval officers from the United States, Hong Kong public hospital experts, investors, and industry representatives. The meeting focused on regulatory policies and commercialization pathways in the industry. The Shenzhen Cell Valley team engaged in in-depth exchanges with global regulatory agencies and industry leaders, sharing practical market experience in China to promote the healthy development of Hong Kong's CGT industry and jointly build an efficient and innovative regulatory and industrial ecosystem.

(Photo of Mr.Yu Changhai, President of Hong Kong Biotechnology Association, with Professor Shi Yuanyuan, Chairman of the Association)